Metabolomic Profiling in Asthma Pathogenesis

Metabolomic profiling has emerged as a pivotal tool for dissecting the biochemical underpinnings of asthma, a global respiratory disorder affecting hundreds of millions. By measuring small-molecule metabolites in biofluids, tissues and exhaled breath condensate, this approach reveals the terminal molecular effects of gene–environment interactions. In asthma pathogenesis, alterations in amino-acid metabolism, energy pathways, lipid mediators and redox balance drive airway inflammation, hyper-responsiveness and tissue remodelling. High-resolution mass spectrometry and nuclear magnetic resonance have characterised distinct metabolic signatures across asthma endotypes, differentiating eosinophilic from neutrophilic phenotypes and correlating with clinical severity measures. Integration with transcriptomic and proteomic data further identifies upstream metabolic enzymes and transporters as potential drug targets. Practical applications include the discovery of non-invasive biomarkers for early diagnosis, prediction of exacerbations and monitoring of therapeutic responses. As metabolomics continues to evolve, it promises to inform precision medicine strategies and novel metabolite-based interventions for asthma management worldwide.

Research from Nature Portfolio

Investigation of lysophosphatidylcholine (LPC) in allergic airway disease has established its central role as a pro-inflammatory lipid mediator. In murine models, allergen challenge induces phospholipase A2-dependent release of LPC in bronchoalveolar lavage fluid, promoting airway hyper-responsiveness, eosinophil influx and Th2-type cytokine release. Pharmacological inhibition of LPC generation attenuates these hallmarks, while exogenous LPC alone reproduces key features of airway inflammation. Mechanistic studies implicate CD1d-restricted natural killer T cells in LPC-driven responses, positioning LPC not merely as a biomarker but as an active driver of asthma pathogenesis and a potential target for lipid-centred therapies.

Metabolomic Profiling in Asthma Pathogenesis publication trend

The graph below shows the total number of articles in metabolomic profiling in asthma pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomics: High-throughput analysis of small molecules (metabolites) in biological samples to profile functional biochemical states.

Metabolite profiling: Quantitative measurement of specific metabolites to detect perturbations in metabolic pathways.

Lysophosphatidylcholine (LPC): A pro-inflammatory lipid mediator generated by phospholipase A2-driven hydrolysis of phosphatidylcholine.

Bronchoalveolar lavage fluid (BALF): Fluid collected from the lower respiratory tract used to sample airway lining components and immune cells.

CD1d-restricted natural killer T cells: A subset of innate-like T cells activated by lipid antigens presented by CD1d molecules.

References

1. Proline is increased in allergic asthma and promotes airway remodeling. JCI Insight (2023).
2. Integration of metabolomics and transcriptomics reveals the therapeutic mechanism underlying Chelidonium majus L. in the treatment of allergic asthma. Chinese Medicine (2024).
3. Metabolomic Analysis Reveals Distinct Profiles in the Plasma and Urine Associated with IgE Reactions in Childhood Asthma. Journal of Clinical Medicine (2020).
4. Lysophosphatidylcholine plays critical role in allergic airway disease manifestation. Scientific Reports (2016).
5. Serum Metabolomics Analysis of Asthma in Different Inflammatory Phenotypes: A Cross‐Sectional Study in Northeast China. BioMed Research International (2018).